



CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

Date: - 14/02/2022

To,

Department of Corporate Services,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
SCRIP CODE: 530843

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Bandra-Kurla
Complex, Bandra (East),
Mumbai - 400051
Fax No. – 6641 8125 / 26
SCRIP CODE: CUPID

Subject: -Outcome of Board Meeting.

Dear Sir / Madam,

With reference to captioned subject, we attached herewith the detail statement of outcome of Board Meeting pursuant to regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records and acknowledge the receipt.

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase



Company Secretary and Compliance Officer

ECSIN: EA041701A000083921

CIN No.: L25193MH1993PLC070846

Factory & Registered Office:

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India

Tel: +91 2551 230280 / 230772 / +91 7722009580 Email: info@cupidlimited.com, Website: www.cupidlimited.com



CUPID LIMITED

Manufacturers and Suppliers of Male & Female Condoms

OUTCOME OF BOARD MEETING

February 14th, 2022:

The Board of Directors of the Cupid Limited at its meeting held on February 14th, 2022, inter alia, had considered and approved the following matters: -

Commencement time of Board Meeting: - 17.53 P.M.

Conclusion time of Board Meeting: - 18.45 P.M.

1. Quarterly reports submitted to BSE Limited and National Stock Exchange of India Limited for quarter ended 31st December, 2021 were considered and reviewed by the Board.
2. Unaudited Standalone and Consolidated Financial Results for quarter ended 31st December, 2021 were considered and adopted by the Board.
3. The Board of Directors nominate and designate Mr. Saurabh Karmase, the Company Secretary and Compliance Officer of the Company as the Nodal Officer under IEPF Rules.
4. The board has considered and approved the mutual termination of Service Provider and Licensing Agreement executed between Cupid Limited and Invex Health Private Limited dated 5th November, 2020 due to other business commitments of the later party. Further, after the said termination, Cupid Limited would manage the entire IVD diagnostic business.
5. The board has considered and approved the sale of 11,65,740 Equity shares (40% of Paid-up Equity Share Capital) and 18,46,154 Compulsory Convertible Debentures (40% of Company's CCD's) along with transfer of management control of an associate company Selo Health Private Limited.

Place: - Mumbai

Date: - 14/02/2022

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase



Company Secretary and Compliance Officer

ECSIN: EA041701A000083921

CIN No.: L25193MH1993PLC070846

Factory & Registered Office:

A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India

Tel: +91 2551 230280 / 230772 / +91 7722009580 Email: info@cupidlimited.com, Website: www.cupidlimited.com